Shared on 26 Jun 26
Fair value Increased 64%LQDA: Legal Outcomes And Earnings Power Will Shape The Next Phase
9 viewsusers have viewed this narrative update
Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.
Shared on 26 Jun 26
Fair value Increased 64%High growth potential with adequate balance sheet.
A biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.